Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia

Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases

(2017) et al.   MOLECULES

Expression and prognostic value of the WEE1 kinase in gliomas

(2016) Darija Music et al.   JOURNAL OF NEURO-ONCOLOGY

Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine

(2015) S. P. Hunger et al.   BLOOD

Personalized medicine in adult acute lymphoblastic leukemia

(2015) D. Hoelzer   HAEMATOLOGICA

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

(2015) Ilaria Iacobucci et al.   Journal of Hematology & Oncology

Personalized medicine in adult acute lymphoblastic leukemia

(2015) D. Hoelzer   HAEMATOLOGICA

Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints

(2014) Neil Beeharry et al.   CELL CYCLE

CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells

(2014) Wenxiu Qi et al.   Journal of Hematology & Oncology

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations

(2014) L Zhou et al.   LEUKEMIA

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

(2013) H. M. Kantarjian et al.   BLOOD

High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients

(2013) Gry Irene Magnussen et al.   BMC CANCER

Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality

(2013) A. A. Van Linden et al.   MOLECULAR CANCER THERAPEUTICS

RNAi screening of the kinome with cytarabine in leukemias

(2012) R. Tibes et al.   BLOOD

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination

(2012) M Krajewska et al.   ONCOGENE

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

(2012) Nicholas M. Levinson et al.   PLoS One

High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy

(2012) Gry Irene Magnussen et al.   PLoS One

Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options

(2012) Theresa Liu-Dumlao et al.   Current Oncology Reports

WEE1 inhibition sensitizes osteosarcoma to radiotherapy

(2011) Jantine PosthumaDeBoer et al.   BMC CANCER

Eukaryotic DNA damage checkpoint activation in response to double-strand breaks

(2011) Karen Finn et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

(2011) K. A. Bridges et al.   CLINICAL CANCER RESEARCH

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells

(2011) J. M. Kreahling et al.   MOLECULAR CANCER THERAPEUTICS

Adult acute lymphoblastic leukemia

(2010) Stefan Faderl et al.   CANCER

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

(2010) Shahryar E. Mir et al.   CANCER CELL

DNA Damage Response

(2010) G. Giglia-Mari et al.   Cold Spring Harbor Perspectives in Biology

Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity

(2009) Ewa Lech-Maranda et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis

(2008) Steffen Blenk et al.   BMC CANCER

Progress in the treatment of adults with acute lymphoblastic leukemia

(2008) Sarah Larson et al.   CURRENT OPINION IN HEMATOLOGY

Cyclin-dependent kinases and cell-cycle transitions: does one fit all?

(2008) Helfrid Hochegger et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY